Background: Dyslipidaemia is a well known risk factor for cardiovascular disease (CVD). Lipid metabolism is affected by a range of genes and proteins. This study investigated whether some of these genes are associated with measures of subclinical CVD. Methods: Polymorphisms of paraoxonase 1 and 2, cholesteryl ester transfer protein, hepatic lipase, and lipoprotein lipase were tested for associations with measures of subclinical CVD including carotid intima-media thickness measured by B-mode ultrasound and carotid and coronary arterial calcification measured by computed tomography. Analysis was performed in 620 European American participants in the Diabetes Heart Study, 83% of whom had type 2 diabetes mellitus. Associations of genotypes with subclinical CVD were tested by computing a series of generalised estimating equations. Results: The Q192R variant of paraoxonase 1 and rs285 of lipoprotein lipase were associated with carotid artery calcium (p values = 0.002 and 0.005, respectively). Paraoxonase 2 S311C was associated with coronary artery calcium (p value = 0.037). Conclusions: There is evidence for modest, but significant, association of multiple single nucleotide polymorphisms in lipid genes with measures of subclinical CVD.
Background: Dyslipidaemia is a well known risk factor for cardiovascular disease (CVD). Lipid metabolism is affected by a range of genes and proteins. This study investigated whether some of these genes are associated with measures of subclinical CVD. Methods: Polymorphisms of paraoxonase 1 and 2, cholesteryl ester transfer protein, hepatic lipase, and lipoprotein lipase were tested for associations with measures of subclinical CVD including carotid intima-media thickness measured by B-mode ultrasound and carotid and coronary arterial calcification measured by computed tomography. Analysis was performed in 620 European American participants in the Diabetes Heart Study, 83% of whom had type 2 diabetes mellitus. Associations of genotypes with subclinical CVD were tested by computing a series of generalised estimating equations. Results: The Q192R variant of paraoxonase 1 and rs285 of lipoprotein lipase were associated with carotid artery calcium (p values = 0.002 and 0.005, respectively). Paraoxonase 2 S311C was associated with coronary artery calcium (p value = 0.037). Conclusions: There is evidence for modest, but significant, association of multiple single nucleotide polymorphisms in lipid genes with measures of subclinical CVD. C ardiovascular disease (CVD) susceptibility is widely believed to be the product of lifestyle and environment interacting with genetic factors. 1 2 In addition to traits such as smoking, body mass index (BMI), hypertension, and gender, major risk factors for CVD include increased triglycerides and low density lipoprotein (LDL) and decreased high density lipoprotein (HDL). Levels of triglycerides, LDL, and HDL and their metabolism are affected by a broad range of genes and their protein products. For example, paraoxonases 1 and 2 (PON1 and PON2), 3 cholesteryl ester transfer protein (CETP), 4 hepatic lipase (HL), 5 and lipoprotein lipase (LPL) 6 are all contributors to the metabolism of lipoproteins. They have previously been the subject of several studies with the goal of identifying genes associated with various metabolic and clinical measures of CVD in several populations with varied results.
In this study, we have investigated common variants of PON1, PON2, CETP, HL, and LPL for association with measures of subclinical CVD in European American individuals from the Diabetes Heart Study (DHS). The DHS is a single centre, family based study, designed to locate and identify genes contributing to CVD in families enriched for type 2 diabetes mellitus (T2DM). 7 8 T2DM is an independent risk factor for CVD and the investigation of diabetic individuals enriches for CVD, providing an improved distribution for measures of subclinical disease over general population samples with little disease. In addition to conventional risk factors, subclinical CVD has been quantitatively assessed in the DHS through measurement of intimamedia thickness (IMT) of the common carotid artery, and coronary artery calcification (CAC) and carotid artery calcification (CarAC). The DHS has shown that both IMT and CAC have a significant heritable component 7 8 and they independently have been shown to correlate with atherosclerosis and clinical CVD, 9-12 making these useful noninvasive surrogate measures.
Several studies have tested for associations between genetic variants in a variety of genes and IMT in both diabetic and non-diabetic populations, 13 although the results have been highly variable. Genetic determinants of CAC have been less intensively studied due to the novelty of the phenotype, but evidence exists that several genes may contribute to this useful marker of atherosclerosis. 14 In the DHS we have the capability to assess genetic association of both IMT and CAC in a set of families enriched for T2DM and atherosclerosis. This makes it a powerful resource for the mapping or identification of genes contributing to CVD.
METHODS
The recruitment and phenotyping of DHS participants have been previously described. 7 8 Briefly, siblings concordant for T2DM with no renal insufficiency were recruited along with any available unaffected siblings. All protocols were approved by the institutional review board of Wake Forest University School of Medicine and all participants gave informed consent. Participant examinations were conducted in the General Clinical Research Center of the Wake Forest University Baptist Medical Center and included interviews for medical history and health behaviours, anthropometric measures, resting blood pressure, fasting blood sampling, and spot urine collection. Laboratory assays included urine albumin and creatinine, total cholesterol, HDL, triglycerides, HbA1c, fasting glucose, and blood chemistries. IMT of the common carotid artery was measured by high resolution Bmode ultrasonography with a 7.5 MHz transducer and a Biosound Esaote (AU5) ultrasound machine as previously described. 7 CAC and CarAC were measured using fast gated helical CT scanners and calcium scores calculated as described previously. 8 In addition to the European American participants the DHS includes an African American component; however, the power to detect genetic association in this ethnic group is limited due to the relatively small numbers of participants (15% of the total cohort) and analyses of this sample are not presented here.
Genetic analysis
Total genomic DNA was purified from whole blood samples obtained from subjects using the PUREGENE DNA Isolation Kit (Gentra, Minneapolis, MN). DNA was quantitated using standardised fluorometric readings on a Hoefer DyNA Quant 200 fluorometer (Hoefer Pharmacia Biotech, San Francisco, CA). Each sample was diluted to a final concentration of 5 ng/ml.
Single nucleotide polymorphisms (SNPs) genotyped were: L55M and Q192R of PON1; S311C of PONI2; rs289714, I405V, and R451Q of CETP; C-480T of HL; and rs285 and rs320 of LPL. SNP rs289714 is referred to in previous literature as intron 9+29ARG. 15 The variants of the LPL gene rs285 and rs320 are referred to in the literature as PvuII and HindIII, respectively. C-629A of CETP was considered for genotyping, however, this variant was not suitable for genotyping on the high throughput Sequenom platform used in this study. In addition, this variant is also in strong linkage disequilibrium with R451Q. SNP genotypes were determined using a MassARRAY SNP genotyping system (Sequenom, San Diego, CA) as previously described. 16 This genotyping system uses single base extension reactions to create allele specific products that are separated and automatically scored in a MALDI-TOF mass spectrometer. Primers for PCR amplification and extension reactions are designed using SpectroDESIGNER assay design software (Sequenom).
Statistical analyses
Allele and genotype frequencies were calculated from unrelated probands and tested for departure from HardyWeinberg proportions using a x 2 test. To test for an association among the polymorphisms of each individual SNP and each trait, a series of generalised estimating equations (GEE1 17 ) was computed. Familial correlation was accounted for by using a sandwich estimator of the variance and exchangeable correlation. Four tests of association were performed for each SNP and trait combination. Specifically, the two degree of freedom overall test of genotypic association and, if significant, the three individual contrasts defined by the a priori genetic models (that is, dominant, additive, recessive) were computed. The dominant model tests for differences between the combined 1/2 and 2/2 genotypes v the 1/1 genotype (that is, presence v absence of allele 2). The additive model tests for a cumulative effect of allele 2. The recessive model tests for differences between genotype 2/2 v 1/1 and 1/2 (that is, two copies of allele 2). Caution should be employed when examining tests of association when the number of individuals within the least common category is small (for example, recessive model with a rare variant). Tests were computed making adjustment for covariates age, gender, diabetes status, smoking status, and lipid lowering medication use. IMT, CAC, and CarAC values were log transformed to best approximate the distributional assumptions of the test and to minimise heterogeneity of variance. A p value of ,0.05 was considered significant.
RESULTS
DNA from 620 European American individuals in 230 families comprising 656 sibling pairs was genotyped. Included in the sample was one single affected individual, 132 pedigrees with one affected sibling pair, 43 trios, 42 pedigrees with four siblings, four pedigrees with five siblings, seven pedigrees with six siblings, and one complex pedigree. Parents were available for only three pedigrees. Of the 620 subjects, 512 have diagnosed T2DM. The clinical characteristics of all European American subjects and the diabetic subset are given in 
Association analysis
The statistical significances for the overall genotypic associations are presented in table 2. Significant associations were detected for PON1 Q192R with CarAC, PON2 S311C with CAC, and LPL rs285 also with CarAC, with the p values ranging from 0.037 to 0.002. Analyses were also conducted in diabetic participants alone with results similar to those with all participants (data not shown). Genotypic means for each trait (untransformed) where a significant association was detected are presented in table 3. The RR genotype of PON1 Q192R was associated with greater carotid calcium, and a smaller percentage of homozygous individuals had a score of 0, suggesting that it is correlated with an increased risk of CVD. Similarly, allele 2 of LPL rs285 was associated with decreased CarAC, and a greater percentage of homozygous individuals had 0 CarAC, indicating a decreased risk of CVD. Allele 2 of PON2 S311C was associated with lower coronary calcium scores also correlating with a decreased risk of CVD, however, the number of individuals with 0 CAC was too small to see a trend.
An inheritance model based analysis may be more powerful than the overall test of association and may provide additional information on the most likely mode of inheritance. However, this study was not statistically powered to distinguish between these models. The inheritance model based analyses were therefore only considered when the overall test of association was significant. The associations of 
DISCUSSION
The results of this study show that several common variants of genes involved in lipid metabolism are significantly associated with subclinical CVD. Specifically, the paraoxonase genes and LPL are associated with measures of arterial calcification. These genes do not appear to be important determinants of common carotid artery IMT. Although it has been shown to be heritable, 8 18 and a genome wide scan has been conducted, 19 very few genes have so far been found to be associated with coronary artery calcium. Among those identified are MMP3, MGP, CCR2, ACE, APOE, E-selectin, EPHX2, and HL, 14 20 21 all of which still require confirmation in independent samples. To this list we now add PON2. Additionally, this is the first report to our knowledge of a genetic association with carotid artery calcium and we present evidence that both PON1 and LPL are associated with this phenotype.
The two paraoxonase genes are associated with calcified arterial plaque, PON1 Q192R in the carotid artery and PON2 S311C in the coronary artery. The literature suggests that the R allele of Q192R has a reduced ability to protect lipids from oxidative modification compared with the Q allele. This has been observed for lipid associated with LDL 22 as well as free lipid in atherosclerotic lesions in both the carotid and coronary arteries. 23 This is consistent with the association of the R allele with coronary heart disease demonstrated in a meta-analysis of case-control studies 24 and the increased CAC score in RR homozygotes observed in the current study.
Furthermore, in this study, the G allele of PON2 S311C, coding for cysteine, appears to reduce levels of coronary artery calcium, indicating that it may reduce the risk of CVD. This study adds to the evidence of PON involvement with CVD through investigation of a subclinical quantitative measure of CVD in a diabetic population.
The LPL gene SNP rs285 was also associated with carotid artery calcium in this study. Rare genetic LPL deficiencies are known to cause severe dyslipidaemias. Several coding variants are known and have been investigated in multiple studies. A meta-analysis indicates that these variants are associated with plasma triglyceride, HDL levels, and possibly ischaemic heart disease, with a small effect size. 25 However, most are rare (minor allele frequencies ,0.05) 26 and therefore in this study we chose to investigate the more common rs285 (PvuII) and rs320 (HindIII) polymorphisms in order to increase the statistical power and improve the chance of detecting a variant making a significant contribution to CVD in European American populations. These intronic SNPs have also been previously associated with coronary artery disease in European Americans 27 28 and while they are probably not functional SNPs, they are likely to be in linkage disequilibrium with causative variants. Haplotypes of the LPL gene have been associated with both insulin resistance and CAD in Mexican Americans, 29 30 although the associations of individual SNPs were weak. The linkage disequilibrium observed between the two polymorphisms in the current study is low (D9 = 0.55) and therefore haplotype analysis with these particular variants is of limited value.
The literature concerning these genes and association with CVD traits is varied and often contradictory. In this case, no association of CETP or HL with CVD was detected despite previous reports that both genes are associated with IMT. 15 31 This is a common theme in genetic research for common but complex traits and can partly be explained by investigations in different populations and subpopulations and by different methodologies. HL was also found to be associated with coronary calcification in type 1 diabetes patients. 21 The different etiologies of type 1 and type 2 diabetes may account for this difference. Type I error (false positive results) may also account for some of the differences between studies, particularly in small sample sizes as in the report by Rundek et al describing an association of the HL gene with IMT in only 87 stroke free individuals. 31 This collection of 620 individuals is one of the larger studies, which should improve power to detect true associations; however, SNP allele frequency combined with the small expected effect size still limits the power and makes stratification of the sample and investigation of complex environmental and genetic interactions uninformative. Corrections for multiple comparisons have not been made. All the SNPs chosen were in candidate genes previously reported as playing a role in CVD and with the exception of the LPL SNPs and CETP rs289714, are potentially functional variants, providing a priori hypotheses for their association with measures of CVD.
There is some chance that the associations detected here are spurious, particularly as the recessive model is most likely and the number of homozygotes for the minor allele of the PON genes is small. In this study only a few variants of each gene were studied. There exists substantially more variation in these genes which may be confounding these results if the marker used is represented on both a risk and a non-risk haplotype. Future work will require in depth investigations of the total genetic variation of each gene as well as subsequent multilocus and haplotype analyses in order to determine those at risk of CVD based on the genetic profile.
These genes all play important roles in lipid metabolism and therefore a contribution of these SNPs to lipid levels could be expected. This predominantly diabetic sample has moderate to severe dyslipidaemia (table 1) and 40% of patients were taking lipid lowering medications which will inevitably affect lipid levels making an accurate assessment of the genetic contribution difficult. The contribution of these genes to lipid levels may be better assessed in a more representative population sample. It is interesting that no associations were detected with carotid IMT, particularly as PON1 appears to be influencing atherosclerosis in the carotid artery. While both IMT and calcification are surrogate measures of CVD, they appear to measure different aspects of the disease, as indicated by the small correlation observed between the traits. 32 CVD and T2DM are complex diseases with many overlapping risk factors and likely have many interdependencies. This study has identified several polymorphisms correlating with subclinical CVD in T2DM families. Specifically, genetic variation of the PON1, PON2, and LPL genes appears to contribute to arterial calcification in a European American diabetic population, suggesting that the pathways involving these genes may be useful therapeutic targets for individuals carrying risk alleles.
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